sign in sign up
<<
Home , Laudanosine, Proadifen

Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

1.0 Purpose

1.1 This document describes procedures employed by the Forensic Toxicology Laboratory to screen blood or other biological specimens for the presence of alkaline-extractable (basic) drugs.

1.2 Biological specimens are basified to a moderately alkaline pH 9.3 at which basic drugs are soluble in organic solvent. The organic layer is separated and the basic drugs are back extracted into 2 N HCl. The acid layer is then made alkaline and basic drugs are re-extracted into an organic solvent. The extracts are analyzed by gas chromatography mass spectrometry (GC/MS) operating in full scan mode.

2.0 Scope

2.1 The assay is appropriate for qualitative detection of chromatographically stable alkaline extractable drugs in whole blood, serum, plasma, urine, bile, stomach contents or tissue homogenates. This methodd could Copyalso be applied to non- biological samples.

3.0 Definitions and Abbreviations 3.1 No method-specific or nonrolle-standard terms are used in this procedure. 4.0 Materials t

4.1 Instruments and Equipment

4.1.1 13 x 100 mm screw top test tubes

4.1.2 Teflon screw caps

4.1.3 Autosampler vials and caps Uncon4.1.4 100 µL Syringe 4.1.5 Vacuum Pump

4.1.6 GC/MS

4.1.7 Varian Factor 4 VF-5MS (15 m x 0.25 mm x 0.25 µm) GC column or equivalent

4.2 Reagents

Page 1 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

4.2.1 Ammonium Hydroxide, Reagent Grade

4.2.2 n-Butyl Chloride (chlorobutanes), HPLC Grade

4.2.3 Saturated Sodium Borate Buffer, pH 9.3 A. To 1000 mL of deionized (DI) water, add sodium borate until no more sodium borate will dissolve. B. Stable for 6 months at room temperature.

4.2.4 Dichloromethane (methylene chloride), HPLC Grade

4.2.5 2 N HCl A. Add 166 mL of concentrated HCl to 500Copy mL deionized water and mix. B. Allow to cool to room temperature. QS to 1000 mL with DI water. C. Stir to mix. D. Stable at room temperature indefinitely.

4.2.6 Methanol, HPLC grade

4.3 Stock Standards and Controls

Note: Certified reference materials shall be used within manufacturer’s expiration date and shall be stored at the recommended storage temperature.

Note: Alternate vendors may be used as long as standards are equivalent.

4.3.1 Commercially prepared stock solutions

Analyte Vendor Catalog Concentration Number Cerilliant M-009 1.0 mg/mL Cerilliant D-015 1.0 mg/mL Chlorpheniramine Cerilliant C-036 1.0 mg/mL UncontrolledCodeine Cerilliant C-006 1.0 mg/mL Cerilliant H-003 1.0 mg/mL Cerilliant V-002 1.0 mg/mL Cerilliant M-007 1.0 mg/mL Cerilliant L-018 1.0 mg/mL Cerilliant C-008 1.0 mg/mL Cerilliant T-027 1.0 mg/mL Amitryptyline Cerilliant A-923 1.0 mg/mL Cerilliant D-907 1.0 mg/mL Cerilliant D-035 1.0 mg/mL Page 2 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Phencyclidine Cerilliant P-007 1.0 mg/mL Cerilliant D-045 1.0 mg/mL Cerilliant V-004 1.0 mg/mL Cerilliant D-013 1.0 mg/mL Propoxyphene Cerilliant P-011 1.0 mg/mL Nordiazepam Cerilliant N-905 1.0 mg/mL Cerilliant M-128 1.0 mg/mL Trazodone Cerilliant T-030 1.0 mg/mL Cerilliant C-060 1.0 mg/mL Cerilliant O-002 1.0 mg/mL Cerilliant Z-901 1.0 mg/mL Norsertraline Cerilliant N-049 0.10 mg/mL Cerilliant N-907 1.0 mg/mL Cerilliant CopyS-021 1.0 mg/mL Cerilliant C-095 1.0 mg/mL Cerilliant M-039 1.0 mg/mL Carisoprodol Cerilliant C-077 1.0 mg/mL Alprazolam Cerilliant A-903 1.0 mg/mL Cerilliant L-025 1.0 mg/mL Cerilliant F-002 0.10 mg/mL

4.3.2 Stock Solution 1.0 mg/mL A. Weigh 11.3 mg of Promethazine HCl into a 10 mL volumetric flask. B. Adjust volume to 10 mL with methanol. C. Stable for 1 year at -10 to -20º C. D. Alternatively, a 1.0 mg/mL prepared promethazine solution may be substituted. (i.e., Cerilliant catalog #P-111 or equivalent)

4.3.3 Internal Standard Stock, SKF-525A 1.0 mg/mL A. Weigh 10 mg SKF-525A ( hydrochloride) and dilute to 10 mL with methanol. B. Stable for 3 years at -10 to -20º C.

Uncontrolled4.4 Working Standards and Controls

4.4.1 Working Positive Basic Control #1 0.01/0.004 mg/mL A. Pipette 100 µL of , cyclobenzaprine, diphenhydramine, methadone, methamphetamine, verapamil, and zolpidem to a 10 mL volumetric flask. B. Pipette 40 µL of chlorpheniramine, hydrocodone, and oxycodone to the same volumetric flask. C. Dilute to 10 mL with methanol. Stable until the earliest manufacturer’s expiration date at -10 to -20º C.

Page 3 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

4.4.2 Working Positive Basic Control #2 0.01 mg/mL A. Pipette 100 µL of , cocaine, diazepam, diltiazem, lidocaine, nortriptyline, promethazine, sertraline, and tramadol to a 10 mL volumetric flask. B. Dilute to 10 mL with methanol. C. Stable until the earliest manufacturer’s expiration date at -10 to -20º C.

4.4.3 Working Positive Basic Control #3 0.01/0.004 mg/mL A. Pipette 100 µL of nordiazepam, doxylamine, mirtazapine, , propoxyphene, trazodone, venlafaxine and citalopram to a 10 mL volumetric flask. B. Pipette 1 mL of norsertraline into the same volumetric flask. C. Pipette 40 µL of dextromethorphan into the same volumetric flask. D. Dilute to 10 mL with methanol. Copy E. Stable until the earliest manufacturer’s expiration date at -10 to -20º C.

4.4.4 Working Positive Basic Control #4 0.01/0.0008 mg/mL A. Pipette 100 µL of alprazolam and levamisole to a 10 mL volumetric flask. B. Pipette 80 µL of fentanyl into the same 10 mL volumetric flask. C. Dilute to 10 mL with methanol. D. Stable until the earliest manufacturer’s expiration date at -10 to -20º C.

4.4.5 Working Internal Standard SKF-525A 0.10 mg/mL A. Transfer 1 mL of stock internal standard to a 10 mL volumetric flask. B. Adjust the volume to 10 mL with methanol. C. Stable for 6 months at -10 to -20º C.

5.0 Procedure

5.1 Control and case sample preparation 5.1.1 Label sufficient 13 x 100 mm screw top test tubes for reagent blank, negative control, positive controls, and case samples.

Uncontrolled5.1.2 Basic Blood Control #1 A. Add 50 µL of working positive basic control #1 to the appropriately labeled tube. Do not dry as methamphetamine will be lost.

5.1.3 Basic Blood Control #2 A. Add 50 µL of working positive basic control #2 to the appropriately labeled tube. Do not dry.

5.1.4 Basic Blood Control #3 A. Add 50 µL of working positive basic control #3 to the

Page 4 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

appropriately labeled tube. Do not dry.

5.1.5 Basic Blood Control #4 A. Add 50 µL of working positive basic control #4 to the appropriately labeled tube. B. Add 50 µL of meprobamate stock control to the same test tube. C. Add 20 µL of carisoprodol stock control to the same test tube. D. Do not dry.

Note: Other drugs may be used to prepare additional controls as necessary. Prepare using 0.01mg/mL concentration if available.

5.1.6 Pipette 2 mL of blank blood into reagent blank, negative control and positive control tubes. Copy

5.1.7 Pipette 2 mL of case specimen into the appropriately labeled tube.

5.1.8 Add 20 µL of 0.10 mg/mL SKF working internal standard into all tubes except reagent blank and vortex.

5.2 Extraction

5.2.1 Add 500 µL of saturated sodium borate and 5 mL of n-butyl chloride. A. In severely decomposed cases or tissues, 100 µL of NH4OH may replace saturated borate to perform a strong basic extraction. Add a set of positive controls and a negative control to be extracted with NH4OH replacement.

5.2.2 Cap and mix on rocker for 15 minutes.

5.2.3 Centrifuge tubes for 5 minutes at 3000 rpm.

5.2.4 Transfer upper organic layer into clean, labeled 13 x 100 mm screw top tube. Uncontrolled 5.2.5 Add 2 mL of 2N HCl.

5.2.6 Cap and mix on rocker for 15 minutes.

5.2.7 Centrifuge tubes for 5 minutes at 3000 rpm.

5.2.8 Discard upper organic layer. Retain the lower aqueous layer.

5.2.9 Add 500 µL of concentrated NH4OH to the aqueous layer and mix well.

Page 5 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Let cool for 2 minutes.

5.2.10 Add 200 µL of dichloromethane.

5.2.11 Cap and vortex for two 30 second intervals.

5.2.12 Centrifuge for 5 minutes at 3000 rpm.

5.2.13 Transfer the bottom organic layer to labeled autosampler vials and place into GC/MS autosampler tray. If the sample will not be analyzed immediately, place them in the freezer for temporary storage.

5.3 GC/MS Acquisition Parameters Copy 5.3.1 Table 1: GC/MS Parameters (SCAN.M)

INJECTOR INLET COLUMN OVEN Injection volume Pulsed splitless VF-5MS (15 m x 0.25 Initial temp 50ºC 0.5-2 µL mm x 0.25 µm) Hold 1 min Syringe size 10 µL Helium Constant flow Ramp 50ºC/min to 100ºC Hold 1 min Temp 250ºC Carrier gas: Helium Ramp 20ºC/min to 285ºC Hold 8 min MSD ACQUISTION MS Source 230°C Scan Mode MS Quad 150°C 40-500 m/z

5.3.2 Table 2: Target Ions

ANALYTE QUANT CONC ANALYTE QUANT CONC ION (mg/L) ION (mg/L) SKF (IS) 86 Nortriptyline 44 0.25 Methamphetamine 58 0.25 Cocaine 182 0.25 Diphenhydramine 58 0.25 Tramadol 58 0.25 UncontrolledChlorpheniramine 203 0.10 Amitriptyline 58 0.25 Codeine 299 0.25 Promethazine 72 0.25 Hydrocodone 299 0.10 Diazepam 256 0.25 Verapamil 303 0.25 Diltiazem 58 0.25 Methadone 72 0.25 Sertraline 274 0.25 Cyclobenzaprine 58 0.25 Citalopram 58 0.25 Zolpidem 235 0.25 Phencyclidine 200 0.25 Lidocaine 86 0.25 Doxylamine 58 0.25 Alprazolam 279 0.25 Levamisole/ 204 0.25

Page 6 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Tetramisole Venlafaxine 58 0.25 Trazodone 205 0.25 Dextromethorphan/ 271 0.10 Oxycodone 315 0.10 Propoxyphene 58 0.25 Norsertraline 119 0.25 Nordiazepam 242 0.25 Meprobamate 83 25 Mirtazapine 195 0.25 Carisoprodol 158 10 Fentanyl 245 0.02

5.3.3 Table 3: Sample Injection Log

Position Sample Number 1 Reagent blank Copy 2 Negative control 3 QC 1 4 QC 2 5 QC 3 6 QC 4 7… Continue with other QCs or samples Middle and end Re-inject one positive of run control after 20 samples and at the end of run

Note: The instrument should be loaded with the blood samples first, followed by any urine and stomach contents with negative controls injected between samples to reduce carryover.

6.0 Data Analysis / Interpretation/ Documentation

6.1 Refer to TOX07.1014 for general data processing and documentation procedures.

Uncontrolled6.2 A macro may be used to process basic screen data: 6.2.1 In data Analysis, load two files:

C:\MSDCHEM\1\METHODS\POS QC.M C:\MSDCHEM\1\DATA\XXXXXX.D

6.2.2 Under Spectrum/Select Library: Select AAFS.L. NIST08.L and SWGDRUG.L are the preferred second and third libraries to utilize when identifying peaks.

Page 7 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

6.2.3 Under Chromatogram/Extract ions: Use m/z range from -0.30 to +0.70.

6.2.4 Under Chromatogram/MS Signal Integration Parameters: Check Smoothing; Start Threshold=0.200; Stop Threshold=0.00 ; Max Peaks=30

6.2.5 Load the Negative QC located in vial position 2 of the sequence log.

6.2.6 Under Quantitate: Select Calculate to calculate the minimum peak area. (Minimum peak area is 1% of the Negative QC internal standard.)

6.2.7 Before processing QCs, lower the minimum peak area to 1000 to ensure smaller peaks are picked up.

6.2.8 Use separate integration events for troublesomeCopy analytes if necessary.

6.2.9 Under Edit Compounds, select User-Defined tab and verify the following:

A. The minimum quality number in A2$ to account for low quality match results is set to 40. B. The key word FRONT is entered in A3$ to ensure whenever the target ion is embedded in the matrix it will invoke background suppression. C. You can also use BACK but it will not work well on tailing peaks.

6.2.10 Set Retention Times under View/EasyID. Click on Compound, then right click on beginning of the peak and drag to the end of the peak. This will set the retention time in the table.

6.2.11 Before updating go to View/QEdit Quant Result: Only the Internal Standard (IS) and its set of compounds that is needed to be updated should be starred. Double click on compound and the quant ion will show up in the window. Right click on beginning of the peak and drag to the end of the peak. This will Q the compounds to be updated. To delete unwanted Uncontrolledcompounds, Double click on compound, then click Qdel, then Exit, then when prompted to save changes click Yes.

6.2.12 Calibrate/Update/Update one Level: When prompted File has previously been Quantitated. Requant now? You must choose NO. In the next window check responses, and Replace, then click on Do Update, then go to Method/Save Method/OK. Repeat steps 9-11 for each control to be updated.

Page 8 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Note: Operators should check the target integrations via QEDIT routinely to ensure that the start of integration is at the front of the peak. If the start of integration is too far to the left of the start peak, the Apex averaging window will be too large and the suppression window will be shifted to the left. This can give unexpected results.

6.2.13 For target compounds, if the match quality from the PBM search is less than the value specified in A2$, the compound is automatically QDELeted from the quant results. QEDLeted compounds are pruned from the quant report and the new file is reprinted.

6.2.14 If a QDELeted target compound is deemed to be actually present in the sample, highlight and/or mark the target compoundCopy on the initial quantitation report, then manually transcribe the target compound onto the Pruned Report . Please notate to refer to the initial quantitation report for concentration levels.

6.2.15 Do update (DO NOT QUANTITATE-ANSWER “NO” AT THE PROMPT when you do calib update. It will delete QEDIT).

6.2.16 Each QC will be updated with its own IS. When cases are processed the software will use the IS for its dependent target compounds.

6.2.17 Save to Method

6.2.18 Go to Tools

6.2.19 Do List

6.2.20 Pick TOX Screen from the option list and add it to the Selected Options. Click OK. Uncontrolled 6.2.21 Pick from Available Data files for processing. Click process.

7.0 Acceptance Criteria 7.1 Refer to TOX07.1014 GC/MS Scan Analyses: Data Processing and Quality Control, Acceptance and Reporting Criteria for general acceptance criteria.

7.2 The following analytes must have the following responses: Sample Representative Analyte Area Count

Page 9 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

QC1 Methadone ≥ 200,000 QC2 Amitriptyline ≥ 400,000 QC3 Citalopram ≥ 150,000 QC4 Carisoprodol ≥ 20,000 All SKF (Internal standard) ≥ 200,000

7.3 If the internal standard is not clearly visible due to the presence of interfering substances, the sample should be repeated with a strong basic extraction. If the strong basic extraction still doesn’t allow for the internal standard to be clearly visible, the sample is considered unsuitable and should be reported as “Specimen not satisfactory”.

7.4 If any acceptance criterion is not satisfied, corrective action must be taken. 7.4.1 Corrective action may include, but is not limitedCopy to, instrument maintenance, replacing the column, cleaning the source, repeating the extraction or remaking standards or reagents.

8.0 Reporting

8.1 TOX07.1014 GC/MS Scan Analyses: Data Processing and Quality Control, Acceptance and Reporting Criteria provides instructions on reporting. The appendix lists drugs known to be detectable by the basic screen procedure.

8.2 Administrative cutoff for basic drugs: 8.2.1 Any level of fentanyl, alprazolam and oxycodone detected in a case sample needs to be confirmed and/or quantitated. 8.2.2 The administrative cutoff for meprobamate and carisoprodol is 2.0 mg/L. 8.2.3 The administrative cut-off for the other basic drugs is 0.03 mg/L. 8.2.4 All basic drugs detected less than the administrative cut-offs are considered negative.

Exceptions can be made if the drug is above the administrative cut-off in another specimen, detected by another analytical method, or prescription information is available. Uncontrolled 9.0 References 9.1 Garriott, James C.; Foerster, Eberhard H.; Hatchett, Don: "A Rapid, Comprehensive Screening Procedure for Basic Drugs in Blood or Tissues by Gas Chromatography", Journal of Analytical Toxicology. Vol. 2, March/April 1978, p. 50-5.

10.0 Revision history

Page 10 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Reviewed Revision Description of Change By Date Changed revision number to 13; Corrected the spelling of “Mirtazapine” throughout the SOP. Update final approver and changed working control expiration dates D. Mike/ 13 to the manufacturer’s expiration date. A. Beard 0813 Added acceptance criteria for each QC and administrative cutoff for case samples (section 7.1.4 and 7.1.7), updated CRM storage and expiration dates, added “or equivalent” to CRM, deleted non-critical instrument parameters, incorporated raise changes, and F. Guale/ 14 added re-injection of positive controls A. Beard 1013 Changed “Approval by” to Toxicology Manager; Changed revision number to 15; Section 5.3.2 Table 2:Copy Included “Tetramisole” and “Methorphan” to list of D. Mike/ names, added qualification of Presumptive positive A. Beard 1213/ 15 results 0714 Section 6.1.2, added statement to clarify reporting “presumptive positive” results; Section 4.3.29, updated Citalopram stock concentration; Section 4.4.5 updated instructions for making Basic QC #3 and changed revision number. Removed statement on reporting of 16 Drug Metabolites. D. Mike 0914/1214 17 Clarified statement in Section 6.1.3 D. Mike 0415 Add Utak controls and remove reporting semi- quantitation of drugs, remove temperature parameter, F. Guale/L. 18 add reporting criteria for NTR, ROT and TR cases Nickell 1115-1/16 Incorporated basic screen macro SOP into data processing section, incorporated basic screen 19 compounds from TOXF.071 T. Gray 08/16

11.0 Attachment(s) or Appendices Uncontrolled

Page 11 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Quant Quant method method Drugs Major Metabolite Note available for available for parent metabolite Amitriptyline Nortriptyline yes yes

Atracurium no no report as present / Noratropine yes no Copy Bupropion metabolites yes no report metabolite as present -epoxide, Carbamazepine Dihydroxycarbamazepine, yes no report metabolite as present Iminostilbene Carisoprodol Meprobamate yes yes Chlordiazepoxide Nordiazepam, Oxazepam yes yes Citalopram Desmethylcitalopram yes no report metabolite as present Benzoylecgonine, Cocaine yes yes cocaethylene Codeine yes yes

Cyclobenzaprine Norcyclobenzaprine yes no report metabolite as present Hydroxydesipramine yes no report metabolite as present Dextromethorphan/ Report parent as methorphan; report / yes no Methorphan metabolite as present Nordiazepam, oxazepam, Diazepam yes yes temazepam Diltiazem Nordiltiazem yes no report metabolite as present Diphenhydramine Nordiphenhydramine yes no report metabolite as present Nordoxepin yes yes

Doxylamine NUncontrolledordoxylamine yes no report metabolite as present Ephedrine/Pseudoephedrine Norephedrine yes no report metabolite as present

Page 12 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Quant Quant method method Drugs Major Metabolite Note available for available for parent metabolite Fentanyl Norfentanyl yes no

Fluoxetine Norfluoxetine yes yes Guaifenesin no Copyreport as present yes

6-Monoaceylmorphine (6- report if 6-MAM and morphine Heroin (diacetylmorphine) no yes MAM), morphine are present Hydrocodone yes yes

Hydromorphone Hydromorphol yes no report metabolite as present Hydroxychloroquine Desethylchloroquin no no report as present Hydroxyzine Norhydroxyzine, cetirizine yes no report metabolite as present Desipramine yes yes

Ketamine yes no report metabolite as present Levamisole/Tetramisole no report as present Levorphanol yes report quant Lidocaine Lidocaine metabolite yes no report as present will elute in subsequent injection; must Desmethylloperamide no no be reanalyzed with negative QC injected after Meperidine Normeperidine yes yes

Meprobamate Hydroxymeprobamate yes no report metabolite as present Methadone EDDP yes yes Methamphetamine Amphetamine yes yes Methocarbamol UncontrolledGuaifenesin yes no report metabolite as present MDMA MDA yes yes

Page 13 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Quant Quant method method Drugs Major Metabolite Note available for available for parent metabolite Ritanilic acid yes yes Metoclopramide yes

Metoprolol yes Copy Midazolam no Report as present Mirtazepine yes Modafinil yes Naproxen yes Nortriptyline yes yes Ondansetron no report as present no report as present Oxycodone yes yes

Papaverine no report as present yes yes Phencyclidine yes Phendimetrazine Phenmetrazine yes yes yes Phenmetrazine yes Phentermine yes Primidone no yes report primidone as present Promethazine NUncontrolledorpromethazine yes no report metabolite as present yes

Page 14 of 15 Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Chief Toxicologist Document Type: GC & GC/MS Procedure No.: TOX07.2002 Title: Standard basic drug screen Rev.: 19

Quant Quant method method Drugs Major Metabolite Note available for available for parent metabolite Propoxyphene yes yes yes

Quetiapine metabolite yes no Copy /quinine no report as present no will elute in subsequent injection Sertraline Norsertraline yes yes

Strychnine no report as present no report as present Temazepam yes yes

Tramadol Desmethyltramadol yes no report metabolite as present meta- Trazodone Chlorophenylpiperazine yes no report metabolite as present (mcpp) Triazolam yes

Venlafaxine Norvenlafaxine yes yes Verapamil yes no report metabolite as present yes Zolpidem yes yes Uncontrolled

Page 15 of 15